Perdagangan Astria Therapeutics, Inc. - ATXS CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | - | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.024874% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | 0.002651% | ||||||||
Waktu biaya inap | 21:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Key Stats
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 2.36-16.28 |
Average Volume (10 days) | 239.64K |
Average Volume (3 months) | 4.84M |
Market Cap | 372.22M |
P/E Ratio | -100.00K |
Shares Outstanding | 27.99M |
Revenue | N/A |
EPS | -3.62 |
Dividend (Yield %) | N/A |
Beta | 0.91 |
Next Earnings Date | May 10, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|
Astria Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 53.503 | 194.976 | 37.435 | 27.088 | 26.371 |
Selling/General/Admin. Expenses, Total | 19.239 | 14.807 | 11.845 | 8.771 | 9.329 |
Research & Development | 34.264 | 180.169 | 25.59 | 18.317 | 17.042 |
Operating Income | -53.503 | -194.976 | -37.435 | -27.088 | -26.371 |
Interest Income (Expense), Net Non-Operating | 1.724 | 0.122 | 0.236 | 0.845 | 0.325 |
Other, Net | -0.055 | -0.058 | -0.101 | -0.05 | 0.176 |
Net Income Before Taxes | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Net Income After Taxes | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Net Income Before Extra. Items | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Net Income | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Income Available to Common Excl. Extra. Items | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
Income Available to Common Incl. Extra. Items | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
Diluted Net Income | -51.834 | -219.349 | -37.3 | -26.293 | -25.87 |
Diluted Weighted Average Shares | 14.6206 | 8.92517 | 3.05864 | 1.86655 | 0.84249 |
Diluted EPS Excluding Extraordinary Items | -3.54527 | -24.5764 | -12.195 | -14.0864 | -30.7067 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -3.54527 | -24.5764 | -12.195 | -14.0864 | -30.7067 |
Revenue | 0 | ||||
Total Extraordinary Items | |||||
Total Adjustments to Net Income | 0 | -24.437 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 14.29 | 12.386 | 11.449 | 15.378 | 9.508 |
Selling/General/Admin. Expenses, Total | 4.699 | 4.688 | 4.832 | 5.02 | 3.815 |
Research & Development | 9.591 | 7.698 | 6.617 | 10.358 | 5.693 |
Operating Income | -14.29 | -12.386 | -11.449 | -15.378 | -9.508 |
Other, Net | 0.009 | -0.048 | -0.015 | -0.001 | -0.016 |
Net Income Before Taxes | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Net Income After Taxes | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Net Income Before Extra. Items | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Net Income | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Income Available to Common Excl. Extra. Items | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Income Available to Common Incl. Extra. Items | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Diluted Net Income | -13.263 | -11.997 | -11.25 | -15.323 | -9.491 |
Diluted Weighted Average Shares | 18.6982 | 13.7424 | 13.017 | 13.017 | 13.0598 |
Diluted EPS Excluding Extraordinary Items | -0.70932 | -0.87299 | -0.86426 | -1.17716 | -0.72673 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -0.70932 | -0.87299 | -0.86426 | -1.17716 | -0.72673 |
Interest Income (Expense), Net Non-Operating | 1.018 | 0.437 | 0.214 | 0.056 | 0.033 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 127.075 | 46.325 | 38.958 | 38.915 | 17.463 |
Cash and Short Term Investments | 125.508 | 44.93 | 36.244 | 37.57 | 16.369 |
Cash & Equivalents | 1.853 | 22.999 | 5.432 | 5.956 | 16.369 |
Short Term Investments | 39 | 20 | 26.345 | 22.276 | 0 |
Prepaid Expenses | 1.446 | 1.274 | 2.237 | 1.345 | 1.094 |
Total Assets | 127.514 | 47.456 | 41.78 | 39.169 | 17.897 |
Property/Plant/Equipment, Total - Net | 0.394 | 0.966 | 2.349 | 0.056 | 0.321 |
Property/Plant/Equipment, Total - Gross | 0.377 | ||||
Accumulated Depreciation, Total | -0.321 | ||||
Other Long Term Assets, Total | 0.045 | 0.165 | 0.473 | 0.198 | 0.113 |
Total Current Liabilities | 5.203 | 6.39 | 5.032 | 4.171 | 6.016 |
Accounts Payable | 1.557 | 1.544 | 1.197 | 1.408 | 0.773 |
Accrued Expenses | 3.646 | 4.846 | 3.835 | 2.763 | 2.432 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 2.479 | |||
Total Liabilities | 5.203 | 6.787 | 6.06 | 4.227 | 6.105 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 0 | 0.397 | 1.028 | 0.056 | 0.089 |
Total Equity | 122.311 | 40.669 | 35.72 | 34.942 | 11.792 |
Common Stock | 0.013 | 0.02 | 0.012 | 0.007 | 0.024 |
Additional Paid-In Capital | 481.709 | 301.546 | 259.305 | 232.243 | 183.202 |
Retained Earnings (Accumulated Deficit) | -455.809 | -260.897 | -223.597 | -197.304 | -171.434 |
Other Equity, Total | 0 | 0 | -0.004 | 0 | |
Total Liabilities & Shareholders’ Equity | 127.514 | 47.456 | 41.78 | 39.169 | 17.897 |
Total Common Shares Outstanding | 13.017 | 3.34746 | 2.07227 | 0.11903 | 0.3941 |
Other Current Liabilities, Total | 0 | 0.332 | |||
Preferred Stock - Non Redeemable, Net | 96.398 | 0 | 0 | 0 | |
Cash | 84.655 | 1.931 | 4.467 | 9.338 | |
Other Current Assets, Total | 0.121 | 0.121 | 0.477 | ||
Total Preferred Shares Outstanding | 0.03146 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 114.221 | 127.075 | 134.522 | 140.052 | 147.684 |
Cash and Short Term Investments | 112.816 | 125.508 | 131.777 | 139.52 | 146.92 |
Cash & Equivalents | 46.687 | 86.508 | 131.777 | 139.52 | 146.92 |
Short Term Investments | 66.129 | 39 | 0 | 0 | 0 |
Prepaid Expenses | 1.121 | 1.446 | 2.624 | 0.411 | 0.643 |
Other Current Assets, Total | 0.284 | 0.121 | 0.121 | 0.121 | 0.121 |
Total Assets | 114.653 | 127.514 | 135.129 | 140.945 | 148.74 |
Property/Plant/Equipment, Total - Net | 0.228 | 0.394 | 0.557 | 0.717 | 0.874 |
Other Long Term Assets, Total | 0.204 | 0.045 | 0.05 | 0.176 | 0.182 |
Total Current Liabilities | 4.967 | 5.203 | 4.7 | 3.988 | 4.406 |
Accounts Payable | 0.931 | 1.557 | 0.574 | 0.619 | 1.809 |
Accrued Expenses | 4.036 | 3.646 | 4.126 | 3.369 | 2.597 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4.967 | 5.203 | 4.7 | 4.046 | 9.004 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0.058 | 4.598 | |
Total Equity | 109.686 | 122.311 | 130.429 | 136.899 | 139.736 |
Preferred Stock - Non Redeemable, Net | 96.398 | 96.398 | 96.398 | 99.77 | 240.881 |
Common Stock | 0.013 | 0.013 | 0.013 | 0.077 | 0.023 |
Additional Paid-In Capital | 484.46 | 481.709 | 480.336 | 475.499 | 329.813 |
Retained Earnings (Accumulated Deficit) | -471.132 | -455.809 | -446.318 | -438.447 | -430.981 |
Total Liabilities & Shareholders’ Equity | 114.653 | 127.514 | 135.129 | 140.945 | 148.74 |
Total Common Shares Outstanding | 13.017 | 13.017 | 13.0095 | 12.8248 | 3.90283 |
Total Preferred Shares Outstanding | 0.03146 | 0.03146 | 0.03146 | 0.03255 | |
Other Equity, Total | -0.053 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 |
Cash From Operating Activities | -43.533 | -30.151 | -32.485 | -26.569 | -23.465 |
Cash From Operating Activities | 0.026 | 0.119 | |||
Non-Cash Items | 5.654 | 168.066 | 1.448 | 1.568 | 1.524 |
Cash Interest Paid | 0 | 0.079 | |||
Changes in Working Capital | 2.647 | -3.305 | 3.367 | -1.87 | 0.762 |
Cash From Investing Activities | -167.129 | -12.555 | 6.3 | -4.082 | -21.905 |
Capital Expenditures | -0.091 | -0.021 | -0.033 | -0.012 | 0 |
Other Investing Cash Flow Items, Total | -167.038 | -12.534 | 6.333 | -4.07 | -21.905 |
Cash From Financing Activities | 144.721 | 104.284 | 40.86 | 25.62 | 44.295 |
Issuance (Retirement) of Stock, Net | 144.721 | 104.284 | 40.86 | 25.62 | 47.143 |
Issuance (Retirement) of Debt, Net | 0 | -2.848 | |||
Net Change in Cash | -65.941 | 61.578 | 14.675 | -5.031 | -1.075 |
Financing Cash Flow Items |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -51.834 | -38.571 | -26.574 | -15.323 | -194.912 |
Cash From Operating Activities | -43.533 | -32.869 | -22.62 | -12.559 | -30.151 |
Non-Cash Items | 5.654 | 5.15 | 3.947 | 2.672 | 168.066 |
Changes in Working Capital | 2.647 | 0.552 | 0.007 | 0.092 | -3.305 |
Cash From Investing Activities | -167.129 | -31.949 | -33.899 | -27.099 | -12.555 |
Capital Expenditures | -0.091 | -0.06 | -0.002 | 0 | -0.021 |
Other Investing Cash Flow Items, Total | -167.038 | -31.889 | -33.897 | -27.099 | -12.534 |
Cash From Financing Activities | 144.721 | 24.324 | 0 | 0 | 104.284 |
Issuance (Retirement) of Stock, Net | 144.721 | 24.324 | 0 | 0 | 104.284 |
Net Change in Cash | -65.941 | -40.494 | -56.519 | -39.658 | 61.578 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 11.9754 | 3351514 | 2974069 | 2022-12-31 | LOW |
Perceptive Advisors LLC | Private Equity | 7.8232 | 2189462 | 908265 | 2022-12-31 | MED |
Fairmount Funds Management LLC | Hedge Fund | 6.7939 | 1901397 | 989661 | 2022-12-31 | HIGH |
Deep Track Capital LP | Hedge Fund | 6.4907 | 1816531 | 1816531 | 2022-12-31 | MED |
Vivo Capital, LLC | Venture Capital | 6.0071 | 1681199 | 681199 | 2022-12-31 | MED |
Cormorant Asset Management, LP | Hedge Fund | 5.8957 | 1650000 | 450000 | 2022-12-31 | MED |
Altium Capital Management LP | Investment Advisor/Hedge Fund | 4.8429 | 1355372 | 910372 | 2022-12-31 | HIGH |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 4.7784 | 1337315 | 680954 | 2022-12-31 | MED |
Logos Global Management LLC | Investment Advisor | 3.0906 | 864960 | 864960 | 2022-12-31 | HIGH |
Ikarian Capital LLC | Hedge Fund | 2.4125 | 675176 | -24264 | 2022-12-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.338 | 654326 | 123173 | 2022-12-31 | LOW |
Rosalind Advisors, Inc. | Hedge Fund | 2.3348 | 653438 | 653438 | 2021-12-31 | LOW |
Tri Locum Partners LP | Hedge Fund | 2.3273 | 651330 | 19751 | 2022-12-31 | HIGH |
Affinity Asset Advisors LLC | Hedge Fund | 1.6882 | 472482 | 72439 | 2022-12-31 | HIGH |
Sphera Funds Management Ltd. | Hedge Fund | 1.677 | 469340 | 469340 | 2022-12-31 | MED |
Ghost Tree Capital, LLC | Hedge Fund | 1.6079 | 450000 | -50000 | 2022-12-31 | HIGH |
Violin (Jonathan) | Individual Investor | 0.9409 | 263321 | 0 | 2022-04-13 | LOW |
Opaleye Management Inc. | Hedge Fund | 0.9351 | 261703 | 128203 | 2022-12-31 | MED |
Medical Strategy GmbH | Investment Advisor | 0.9026 | 252605 | -18814 | 2022-09-30 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 0.804 | 225000 | 225000 | 2022-12-31 | HIGH |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group500K+
Trader
92K+
Klien aktif per bulan
$53M+
Volume investasi per bulan
$30M+
Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Bio Therapeutic Drugs |
75 State Street
Suite 1400
BOSTON
MASSACHUSETTS 02109
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com